Biography
Wenxin Wang is a Full Professor in Skin Research and Wound Healing, a Science Foundation Ireland (SFI) Principal Investigator at the Charles Institute of Dermatology, School of Medicine, University College Dublin (UCD), and a member of UCD Academic Council. He won the highly prestigious “Young Scientist Prize in Regenerative Medicine” in 2010 at the TERMIS-EU conference, the “SFI Principal Investigator award” in 2011, and the DEBRA Award for Excellent EB Patient Service in 2014, which highlight his work ethic and achievements. Prof. Wang’s scientific interests are in the areas of biomaterials, stem cell, and gene therapy for the treatments of skin wounds, cardiovascular and neural degenerative diseases. His scientific contribution and achievements have been recognized both nationally and internationally including over 200 peer-reviewed scientific journal papers (Nat. Commun., Nat. Rev. Chem., Sci. Adv., Angew. Chem., JACS, Chem. Sci. and Nano Letters, etc.), 5 book chapters, 24 patents, 140 conference abstracts and presentations, and 110 invited lectures and keynote presentations. Since 2009 he has graduated 19 Ph.D. students and mentored over 25 postdoctoral researchers. His achievements have gained the increased interest in the wider public community with publicity media activities (56 times in TV Documentary, Videos, and Newspapers), for example in RTE-TV, ‘The Sunday Times’, ‘The Irish Times, ‘Science Daily’ and ‘Chemistry World’. He has been awarded significant funding (ca. 11.3 million Euros) from different sources, e.g., SFI, Health Research Board (HRB), Irish Research Council (IRC), Enterprise Ireland (EI), and European Union (EU-FP7 & EU Horizon 2020) to support his research activities. Prof. Wang has acted as the symposium convener and chair, the member of organizing committees, and the member of the conference advisory board for 29 international conferences and has been selected as an expert reviewer and panel member by 25 international research councils and funding bodies. As the founder, Prof Wang has launched 3 companies - Vornia Ltd (www.vornia.com, acquired by Ashland - a Fortune500 US company in Jan. 2018, renamed as Ashland Specialties Ireland), Blafar Ltd. (www.blafar.com), and Branca Bunús Ltd. (www.brancabunus.com). Furthermore, he has licensed 7 new technologies to 4 companies: Ashland, Amryt Biopharm, Blafar, and Branca Bunús, and successfully launched and commercialized 5 newly developed technologies onto the market.